Who We Are
Forging new paths with a shared vision
The core of VYNE Therapeutics™ is a hand-picked team of pharmaceutical industry professionals from all over the world who have come together to push past the conventional thinking they encountered in more traditional corporate structures. Our team has long-standing research and development experience, paired with strong commercial experience. We have a combination of diverse perspectives and industry experience necessary to recognize where conventional approaches fall short, and we are passionate about developing new and unexpected solutions to improving patient care.
From its foundation as a technically focused company solving intractable challenges in topical formulation, VYNE Therapeutics is emerging as an entrepreneurial and technology-savvy company of independent thinkers who are dedicated to bringing previously unavailable products to doctors and patients in need of innovation.
Our Board of Directors
Sharon Barbari has served as a member of our board of directors since March 2020. Ms. Barbari previously served as Chief Financial Officer at Cytokinetics from 2004 to 2017 and as CFO at Gilead Sciences, where she served senior financial roles from 1998 to 2002. Ms. Barbari also served as CFO and Senior Vice President of Finance and Administration at InterMune, and Vice President of Strategic Planning at Foote, Cone & Belding Healthcare. From 1972 to 1990, Ms. Barbari served in various roles of increasing responsibility at Syntex Corporation/Roche Pharmaceuticals.
Ms. Barbari currently serves on the board of directors of Sonoma Pharmaceuticals and the Association of Bioscience Finance Officers. She previously served on the board of directors of Foamix Pharmaceuticals Ltd. from January 2019 until its combination with Menlo Therapeutics Inc. (renamed VYNE Therapeutics Inc.), and for Phytogen Life Sciences. In 2017, Ms. Barbari was a recipient of the YWCA Silicon Valley Tribute to Women Awards. She received her BS in accounting from San Jose State University.
Mr. Basta has served as a member of our board of directors since September 2015 and also served as our President and Chief Executive Officer from 2015 to March 2020. Mr. Basta previously served as CEO of AlterG, Inc. a privately-held medical device company from 2011 to 2015, as Chief Executive Officer of BioForm Medical, which was acquired by Merz, from 2002 through 2010, and as Chief Executive Officer of Merz Aesthetics, the successor to BioForm Medical, from February 2010 to September 2011. Prior to Bioform Medical, Mr. Basta served as President and CEO of Gliatech, Inc., VP Business Development and Chief Financial Officer of Creative BioMolecules, Inc., and Executive Director of Product Development for The Immune Response Corporation.
Mr. Basta is currently a board member of Viveve Medical (since September 2018) and serves as Chairman of the Board of Viveve (since January 2019). Mr. Basta previously served on the board of Carbylan from September 2009 to November 2016 and on the board of RF Surgical (acquired by Medtronic) from December 2013 to August 2015. Mr. Basta received his M.B.A. from the Kellogg Graduate School of Business at Northwestern University, and his B.A. in biomedical engineering from The Johns Hopkins University.
Rex Bright has served as a member of our board of directors since March 2020. Mr. Bright founded and served as President and CEO of SkinMedica until it was acquired by Allergan in 2012. Prior to SkinMedica, Mr. Bright was President of Allergan Skincare and spent 19 years at Johnson & Johnson leading their dermatology division. Mr. Bright currently serves on the board of directors of Clarify Medical and MDRejuvenia. He previously served on the board of Foamix Pharmaceuticals Ltd. since 2014, until its combination with Menlo Therapeutics Inc. (renamed VYNE Therapeutics Inc.), and on the board of directors of RestorGenex, Inc. through the company’s merger with Diffusion Pharmaceuticals in 2016. He completed executive programs at Harvard, Stanford, and Northwestern University, and holds a BA in business administration from Drury University in Springfield, Missouri.
Tony Bruno has served as a member of our board of directors since March 2020. Mr. Bruno served in executive roles at Warner Chilcott from 2000 to 2011, most recently as Executive Vice President for business development and as General Counsel. From 1984 to 2000, Mr. Bruno held several positions of increasing responsibility within Warner Lambert’s legal division, culminating as General Counsel to the company’s pharmaceutical business. Mr. Bruno began his legal career at Shearman & Sterling in 1981. Mr. Bruno previously served on the board of Foamix Pharmaceuticals Ltd. from November 2018 until its combination with Menlo Therapeutics Inc. (renamed VYNE Therapeutics Inc.). He received a JD from George Washington Law School, and a BA in political science from Syracuse University.
David Domzalski has served as our President and Chief Executive Officer and member of our board since March 2020. Previously, since July 2017, Mr. Domzalski was Chief Executive Officer and a member of the board of Foamix Pharmaceuticals Ltd. Mr. Domzalski was with Foamix since April 2014, and previously served as President. He has 25 years of industry experience, previously holding positions as Vice President, Sales and Marketing, at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President, Sales and Marketing, at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a BA in economics and political science from Muhlenberg College, Allentown, Pennsylvania.
Patrick G. LePore
Patrick G. LePore has served as a member of our board of directors since September 2020. Mr. LePore previously served as Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies, Inc. from September 2006 until its sale to affiliates of TPG Capital in 2012. He remained as chairman of Par Pharmaceutical through its sale to Endo International in 2015. Mr. LePore began his career with Hoffmann-LaRoche. He later founded Boron, LePore & Associates, a medical communications company, which he took public in 1997 and was eventually sold to Cardinal Health in 2002. Mr. LePore is currently Chairman of the Board of Lannett Co. Inc., Vice Chair of Matinas BioPharma and is a trustee of Villanova University. He previously served on the boards of PharMerica and Innoviva. Mr. LePore earned a bachelor’s degree from Villanova University and a Master of Business Administration from Farleigh Dickinson University.
Ms. Sandoval has served as a member of our board of directors since 2018. Ms. Sandoval currently serves as a senior consultant to the pharmaceutical industry. Previously, from 2016 to 2019, she served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a clinical stage company focused on developing novel therapeutic antibodies for the treatment of migraine. Prior to this, Ms. Sandoval was Chief Commercial Officer for KYTHERA Biopharmaceuticals until KYTHERA’s acquisition by Allergan. Before KYTHERA, Ms. Sandoval served as Vice President of Marketing for Bausch and Lomb Surgical and Vice President of Global Marketing at Allergan with responsibility for the Medical Aesthetics division. She spent 23 years at Allergan in sales and marketing leadership roles in the specialties of dermatology, neurology, and aesthetics. Ms. Sandoval began her career in research and development at Johnson & Johnson’s Ethicon division.
Ms. Sandoval serves on the board of directors for Alastin Skincare, a privately held company. She holds an MBA from Pepperdine University and a B.S. in biology from the University of California, Irvine.